Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
22 hedge funds and large institutions have $1.33M invested in Cyclo Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
16% more funds holding
Funds holding: 19 → 22 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less capital invested
Capital invested by funds: $1.8M → $1.33M (-$463K)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$29.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$894 |
| 3 |
BlackRock
New York
|
+$209 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21 |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$34.7K |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$3.55K |
| 3 |
PGAM
Princeton Global Asset Management
Princeton,
New Jersey
|
-$2.73K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$571 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$327 |
CYTH Hedge Fund Activity: Q4 2024 in Review
22 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q4 2024, worth a combined $1.33M — down 26% from $1.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTH positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $29.5K. The largest seller was EPIQ Capital Group, cutting an estimated $34.7K.
- 22 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $1.33M of Cyclo Therapeutics, Inc. Common Stock stock for Q4 2024, down 26% quarter-over-quarter.
- 4 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q4 2024 and 1 closed out, a net change of +3 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q4 2024 was Two Sigma Securities, an estimated $29.5K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q4 2024 was EPIQ Capital Group, an estimated $34.7K sold.
Based on aggregated 13F filings for Q4 2024.